Ademi LLP probes GeneDx for possible securities fraud over financial statements.

Ademi LLP has launched an investigation into potential securities fraud claims against GeneDx, citing concerns over inaccurate statements related to the company's financial reports, business operations, and future prospects. This investigation aims to uncover whether GeneDx misled investors through false or misleading disclosures. Investors and shareholders are invited to join the investigation or seek more information at no cost. The outcome could impact GeneDx's reputation and stock performance depending on the findings.